Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Understanding your genetic context in GLP-1 and metabolic pathways can support a more informed, confident conversation with your provider about formulation choice, expected timeline to efficacy, and personalization strategies
Polley pointed out that even patients with similar clinical profiles might prioritize different aspects of their health or quality of life
You may be a candidate if you have a BMI of 27 or higher with a weight-related health condition (or 30 or higher without one), have tried diet and exercise without desired results, prefer a non-surgical option, and are committed to lifestyle changes
Furthermore, the role of GLP-1R agonists in the treatment of neurodegenerative diseases such as Alzheimers disease (AD) and Parkinsons disease (PD) is being actively explored (Siddeeque et al., 2024)
Read our MEDvi review for more detailed information
Understanding variants in GLP1R, GIPR, FTO, and MC4R can support a more informed conversation with your provider about whether a lower-cost microdose protocol or a higher-potency compound better aligns with your predicted metabolic response
.png)
